Physiologically Based Pharmacokinetic (PBPK) Modeling of FIX in Pediatric Hemophilia B: Extravascular Distribution and Dosing Optimization
Pharmaceutics · 20.08.2026 · 18 (8) · 1030
DOI: 10.3390/pharmaceutics18081030 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 20.08.2026. Verfasst von Mengmeng Liu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Peking University Third Hospital, Beijing 100191, China. Die Arbeit nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Peking University Third Hospital, Beijing Municipal Administration of Hospitals.
Abstract (Originalsprache)
Background
Prophylaxis in children with hemophilia B (HB) lacks quantitative approaches that integrate both plasma exposure and tissue distribution. This study aimed to develop and validate a physiologically based pharmacokinetic (PBPK) model of factor IX (FIX) for pediatric HB. The model incorporated the binding of FIX to type IV collagen (Col4) to characterize its distribution in both plasma and extravascular tissues.
Methods
A total of 20 children with severe HB were included, contributing 219 plasma samples. The base PBPK model was first established and verified using adult and plasma-derived FIX (pdFIX) data. It was subsequently extrapolated to children by integrating FIX-CTBB parameters and pediatric observations for model calibration. The validated model was used to characterize plasma pharmacokinetics, predict tissue distribution and target attainment, and simulate alternative prophylactic dosing regimens.
Results
The model adequately described the plasma pharmacokinetics of FIX in children and predicted substantial extravascular distribution. Total extravascular exposure was approximately sixfold higher than plasma exposure. Marked heterogeneity in target attainment was identified across tissues. Lower target attainment was observed in the colon, pancreas, and brain, whereas delayed attainment occurred in bone and muscle. Simulations of prophylactic dosing regimens suggested that 75 IU/kg twice weekly may provide a favorable balance among sustained FIX exposure, tissue-level target attainment, and treatment burden.
Conclusions
This PBPK model provides a mechanistic and quantitative framework for characterizing plasma and tissue exposure to FIX in children with HB and may support individualized optimization of FIX prophylactic dosing.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmacy, Peking University Third Hospital, Beijing 100191, China.
- Hemophilia Comprehensive Care Center, Hematology Department, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing 100045, China.
ORCID-Profile: Mengmeng Liu, Haojie Xu
Förderung
- Peking University Third Hospital
- Beijing Municipal Administration of Hospitals
Zitieren
APA
Liu, M., Liu, G., Ling, Q., Chen, Y., Xu, H., Wu, R., Chen, Z., & Zhao, L. (2026). Physiologically Based Pharmacokinetic (PBPK) Modeling of FIX in Pediatric Hemophilia B: Extravascular Distribution and Dosing Optimization. Pharmaceutics, 18(8), 1030. https://doi.org/10.3390/pharmaceutics18081030
Vancouver
Liu M, Liu G, Ling Q, Chen Y, Xu H, Wu R, et al. Physiologically Based Pharmacokinetic (PBPK) Modeling of FIX in Pediatric Hemophilia B: Extravascular Distribution and Dosing Optimization. Pharmaceutics. 2026;18(8):1030. doi:10.3390/pharmaceutics18081030
BibTeX
@article{Liu2026,
author = {Liu, Mengmeng and Liu, Guoqing and Ling, Qixian and Chen, Yongbo and Xu, Haojie and Wu, Runhui and Chen, Zhenping and Zhao, Libo},
title = {Physiologically Based Pharmacokinetic (PBPK) Modeling of FIX in Pediatric Hemophilia B: Extravascular Distribution and Dosing Optimization},
journal = {Pharmaceutics},
year = {2026},
volume = {18},
number = {8},
pages = {1030},
doi = {10.3390/pharmaceutics18081030}
}
EUVIMED